loobobilly News: A Look At How The Revolving Door Spins From FDA To Industry

A Look At How The Revolving Door Spins From FDA To Industry About 27 percent of Food and Drug Administration reviewers who approved hematology-oncology drugs from 2001 through 2010 left to work for the industry they previously regulated, an analysis found. About 27 percent of Food and Drug Administration reviewers who approved hematology-oncology drugs from 2001 through 2010 left to work for the industry they previously regulated, an analysis found. Business
About 27 percent of Food and Drug Administration reviewers who approved hematology-oncology drugs from 2001 through 2010 left to work for the industry they previously regulated, an analysis found.

Read more on NPR